WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 6 fonti

Foundayo and Zepbound now covered for millions of Americans

Foundayo and Zepbound now covered for millions of Americans

Raccontata dabiopharmadive.commorningstar.comcnbc.comqz.comendpoints.newsupi.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
morningstar.comStai leggendo13 h fa

Foundayo and Zepbound now covered for millions of Americans

Foundayo and Zepbound now covered for millions of Americans

originale
upi.com

Timeline cronologica

  1. giovedì 28 maggio 2026·biopharmadive.com

    CVS obesity drug deal puts Lilly on equal footing with Novo

    The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

  2. giovedì 28 maggio 2026·morningstar.com

    Foundayo and Zepbound now covered for millions of Americans

    Foundayo and Zepbound now covered for millions of Americans

6 h fa

CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.

Leggi questa versione → originale
qz.com12 h fa

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

Leggi questa versione → originale
endpoints.news6 h fa

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.

Leggi questa versione → originale
cnbc.com13 h fa

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Leggi questa versione → originale
biopharmadive.com23 h fa

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Leggi questa versione → originale
giovedì 28 maggio 2026·cnbc.com

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

  • giovedì 28 maggio 2026·qz.com

    CVS Caremark adds Zepbound and Foundayo to formulary

    The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

  • giovedì 28 maggio 2026·endpoints.news

    Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

    Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.

  • giovedì 28 maggio 2026·upi.com

    CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com

    CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.